These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism. Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799 [TBL] [Abstract][Full Text] [Related]
29. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways. Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567 [TBL] [Abstract][Full Text] [Related]
30. Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice. Kohlhas V; Hallek M; Nguyen PH Blood Adv; 2020 Dec; 4(24):6106-6116. PubMed ID: 33351104 [TBL] [Abstract][Full Text] [Related]
31. Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. Zaborsky N; Gassner FJ; Höpner JP; Schubert M; Hebenstreit D; Stark R; Asslaber D; Steiner M; Geisberger R; Greil R; Egle A Leukemia; 2019 Apr; 33(4):957-968. PubMed ID: 30262843 [TBL] [Abstract][Full Text] [Related]
32. Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Kohlhaas V; Blakemore SJ; Al-Maarri M; Nickel N; Pal M; Roth A; Hövelmeyer N; Schäfer SC; Knittel G; Lohneis P; Nikolic M; Wiederstein JL; Franitza M; Georgomonolis T; Reinart N; Herling M; Herling C; Hartmann EM; Rosenwald A; Klapper W; Büttner R; Moia R; Rossi D; Boldorini R; Gaidano G; Frenzel LP; Reinhardt HC; Brüning JC; Hallek M; Krüger M; Peifer M; Pallasch CP; Wunderlich FT Blood; 2021 Feb; 137(5):646-660. PubMed ID: 33538798 [TBL] [Abstract][Full Text] [Related]
33. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254 [TBL] [Abstract][Full Text] [Related]
34. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528 [TBL] [Abstract][Full Text] [Related]
35. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Enzler T; Kater AP; Zhang W; Widhopf GF; Chuang HY; Lee J; Avery E; Croce CM; Karin M; Kipps TJ Blood; 2009 Nov; 114(20):4469-76. PubMed ID: 19755673 [TBL] [Abstract][Full Text] [Related]
36. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Herling M; Patel KA; Khalili J; Schlette E; Kobayashi R; Medeiros LJ; Jones D Leukemia; 2006 Feb; 20(2):280-5. PubMed ID: 16341048 [TBL] [Abstract][Full Text] [Related]
37. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Pekarsky Y; Palamarchuk A; Maximov V; Efanov A; Nazaryan N; Santanam U; Rassenti L; Kipps T; Croce CM Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19643-8. PubMed ID: 19064921 [TBL] [Abstract][Full Text] [Related]